Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced equity awards granted on May 11, 2015, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to the employment of two individuals hired by Sarepta in May 2015. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 117,000 shares of Sarepta's common stock. The options have an exercise price of $15.04 per share, which is equal to the closing price of Sarepta's common stock on May 11, 2015. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]

Source: Sarepta Therapeutics, Inc.

You May Also Be Interested In

• Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
• DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Perion Network Ltd. (Nasdaq: Peri) and Lead Plaintiff Deadline
• Bombardier Announces the Election of its Board of Directors